Journal of Vaccines & Vaccination

Development of a new staphylococcal enterotoxin B vaccine candidates

Joint Event on 32^nd International Conference on Vaccines and Immunization & 4^th Annual Summit on Infancy, Child Nutrition & Development

November 09-10, 2018 | Atlanta, USA

Na Young Kim, Sung Hyun Hong, Won Rak Son, Chi Ho Yu, Gyeung Haeng Hur, Sungyoul Hong, Young Kee Shin and Jun Young Choi

ABION Inc., R&D Center, Republic of Korea
Agency for Defense Development, Republic of Korea
Seoul National University, Republic of Korea

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

Staphylococcal enterotoxin B (SEB), produced by the gram-positive bacterium Staphylococcus aureus, is responsible for food poisoning and toxic shock syndrome and is considered a potential bioterrorism agent. Recently SEB vaccine (STEBVax) has completed Phase 1 clinical trials. However, there are still no approved vaccines available against SEB. In this study, we constructed a series of nontoxic SEB mutants (mSEBs) and examined whether these mSEBs provide protective immunity against SEB challenge. These mSEB vaccine candidates did not demonstrate superantigen activity in mouse splenocyte cultures. Immunization with the vaccine candidates triggered the production of IgG antibodies with neutralizing activity. In addition, increased production of IgG1 and IgG3 was observed after immunization, which signifies both Th1- and Th2-induced immune responses. Among the vaccine candidates tested, S9, a double mutant (N23A and Y90A) and S19, a quadruple mutant (N23A, Y90A, R110A, and F177A), demonstrated complete protection against a lethal SEB challenge. Through this present study, we introduce new vaccine candidates against SEB which are able to induce robust immunogenicity including full protection, neutralization of superantigen activity and the potential to elicit both humoral and cellular immune responses. Our results broaden the perspectives for future initiatives in SEB vaccine development.

Biography :

Na Young Kim has completed her PhD at the age of 30 years from Sogang University and postdoctoral studies from Research Institute for Basic Science in Sogang University. She is the Chief of Researcher of ABION Cor., a bio pharmaceutical drugs and companion diagnostics development organization. She has published more than 14 papers in reputed journals and has been studying about the vaccine development.

E-mail: elf4040@hanmail.net